HeartSciences Announces Allowance of U.S Patent for AI-ECG Assessment of Left Ventricular and Right Ventricular Heart Dysfunction

Stock Information for Heart Test Laboratories Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Heart Test Laboratories Inc.

HeartSciences Provides Business Update and Reports Fiscal 2024 Financial Results
HeartSciences Selected to Demonstrate MyoVista® wavECG(TM) at the United Nations General Assembly Digital Health Symposium as a Technology to Radically Transform Healthcare
HeartSciences Regains Compliance with Nasdaq Listing Requirements
HeartSciences Announces Further Internationalization of its AI-ECG Patent Portfolio
HeartSciences Announces Grant of Fundamental Patent by the European Patent Office Covering Assessment of Diastolic Function of the Heart Using AI-ECG
HeartSciences to Present at the LD Micro Invitational XIV Conference
HeartSciences Announces Podium Presentation at World Congress of Anesthesiologists on the Utility of MyoVista® Wavelet ECG For Detection of Left Ventricular Diastolic Dysfunction in Preoperative Patients
HeartSciences Reports Third Quarter Fiscal 2024 Financial Results

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.